Market Cap 598.70M
Revenue (ttm) 0.00
Net Income (ttm) -183.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,736,700
Avg Vol 1,073,284
Day's Range N/A - N/A
Shares Out 50.52M
Stochastic %K 18%
Beta -0.15
Analysts Strong Sell
Price Target $31.67

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
55 Cambridge Parkway, Suite 901 East, Cambridge, United States
edelhead
edelhead Oct. 2 at 4:21 PM
$KALV the company adds a director, and announces approval of all proposals at the annual meeting - sounds very positive to me. The stock is tanking anyway - we live in bizarro world!
1 · Reply
TwongStocks
TwongStocks Oct. 2 at 11:33 AM
$KALV Bethany L. Sensenig, CFO at Radius Health, appointed to the Board of Directors. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-appointment-bethany-l
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 1 at 11:49 AM
$FBIO it has happened before. $KALV was delayed for weeks a few months ago due to RFKJ’s cuts to the FDA. This shutdown and banana republic leadership in Washington isn’t helping manners. Hopefully we find out soon 🕰️
0 · Reply
highnihilism
highnihilism Oct. 1 at 7:25 AM
$HIPO Hippo Holdings Trade Count: 9 | Total $: 9.2 K | 0.14 × 90-Day Avg $: 66.2 K | Call $: 7.7 K | Put $: 1.5 K | % Single-Leg: 93% | % Multi-Leg: 7% | % Contingent: – $KALV Kalvista Pharmaceuticals Trade Count: 20 | Total $: 14.1 K | 0.16 × 90-Day Avg $: 90.7 K | Call $: 7.7 K | Put $: 6.4 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $FCG First Trust Natural Gas ETF Trade Count: 15 | Total $: 20.8 K | 2.99 × 90-Day Avg $: 6.9 K | Call $: 7.7 K | Put $: 13.1 K | % Single-Leg: 99% | % Multi-Leg: 1% | % Contingent: – $MERC Mercer Intl Trade Count: 17 | Total $: 7.7 K | 0.43 × 90-Day Avg $: 17.8 K | Call $: 7.7 K | Put $: 10 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
buckdatrend13
buckdatrend13 Sep. 29 at 9:51 PM
$KALV Ten analysts have an average one-year price target of $32!!!!
1 · Reply
MakeMoneyAZ
MakeMoneyAZ Sep. 26 at 4:40 PM
$KALV Bought more. Whats the consensus on this? When we mooning?
0 · Reply
edelhead
edelhead Sep. 25 at 6:53 PM
$KALV This stock price reaction today is unbelievably ridiculous. You would think from the drop that there is immediate dilution coming at $12. BUT THAT IS NOT WHAT IS HAPPENING IN REALITY. I am frustrated for one reason - because I don't enough cash to buy more shares at this artificially and insanely depressed price!!
0 · Reply
edelhead
edelhead Sep. 25 at 4:05 PM
$KALV The market reaction today should be the opposite from what is happening. It seems like the potential future dilution is approx. 15%, but only if the stock price first goes up approx. 40%. And in the meantime the company can use the $125 mill to support its worldwide growth. Maybe I'm missing something, but I'm liking this convertible bond deal.
1 · Reply
CH_Expat
CH_Expat Sep. 25 at 3:53 PM
$KALV Almost there.
0 · Reply
redrussian
redrussian Sep. 25 at 1:54 PM
$KALV $ACU stopped out kalv sold acu 42.00
0 · Reply
Latest News on KALV
US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 3 months ago

US FDA approves KalVista Pharma's swelling disorder drug


KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 6 months ago

KalVista: Poised For Rare Disease Transformation


KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 16, 2024, 7:00 AM EST - 10 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer


edelhead
edelhead Oct. 2 at 4:21 PM
$KALV the company adds a director, and announces approval of all proposals at the annual meeting - sounds very positive to me. The stock is tanking anyway - we live in bizarro world!
1 · Reply
TwongStocks
TwongStocks Oct. 2 at 11:33 AM
$KALV Bethany L. Sensenig, CFO at Radius Health, appointed to the Board of Directors. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-appointment-bethany-l
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 1 at 11:49 AM
$FBIO it has happened before. $KALV was delayed for weeks a few months ago due to RFKJ’s cuts to the FDA. This shutdown and banana republic leadership in Washington isn’t helping manners. Hopefully we find out soon 🕰️
0 · Reply
highnihilism
highnihilism Oct. 1 at 7:25 AM
$HIPO Hippo Holdings Trade Count: 9 | Total $: 9.2 K | 0.14 × 90-Day Avg $: 66.2 K | Call $: 7.7 K | Put $: 1.5 K | % Single-Leg: 93% | % Multi-Leg: 7% | % Contingent: – $KALV Kalvista Pharmaceuticals Trade Count: 20 | Total $: 14.1 K | 0.16 × 90-Day Avg $: 90.7 K | Call $: 7.7 K | Put $: 6.4 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $FCG First Trust Natural Gas ETF Trade Count: 15 | Total $: 20.8 K | 2.99 × 90-Day Avg $: 6.9 K | Call $: 7.7 K | Put $: 13.1 K | % Single-Leg: 99% | % Multi-Leg: 1% | % Contingent: – $MERC Mercer Intl Trade Count: 17 | Total $: 7.7 K | 0.43 × 90-Day Avg $: 17.8 K | Call $: 7.7 K | Put $: 10 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
buckdatrend13
buckdatrend13 Sep. 29 at 9:51 PM
$KALV Ten analysts have an average one-year price target of $32!!!!
1 · Reply
MakeMoneyAZ
MakeMoneyAZ Sep. 26 at 4:40 PM
$KALV Bought more. Whats the consensus on this? When we mooning?
0 · Reply
edelhead
edelhead Sep. 25 at 6:53 PM
$KALV This stock price reaction today is unbelievably ridiculous. You would think from the drop that there is immediate dilution coming at $12. BUT THAT IS NOT WHAT IS HAPPENING IN REALITY. I am frustrated for one reason - because I don't enough cash to buy more shares at this artificially and insanely depressed price!!
0 · Reply
edelhead
edelhead Sep. 25 at 4:05 PM
$KALV The market reaction today should be the opposite from what is happening. It seems like the potential future dilution is approx. 15%, but only if the stock price first goes up approx. 40%. And in the meantime the company can use the $125 mill to support its worldwide growth. Maybe I'm missing something, but I'm liking this convertible bond deal.
1 · Reply
CH_Expat
CH_Expat Sep. 25 at 3:53 PM
$KALV Almost there.
0 · Reply
redrussian
redrussian Sep. 25 at 1:54 PM
$KALV $ACU stopped out kalv sold acu 42.00
0 · Reply
DB1984
DB1984 Sep. 25 at 1:30 PM
$KALV fkn Kalvin.
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 25 at 1:05 PM
$KALV (-7.2% pre) KalVista prices $125 million convertible notes offering at 3.250% https://ooc.bz/l/78393
0 · Reply
Shakattack31
Shakattack31 Sep. 25 at 9:53 AM
$KALV grate company with lrage growth potential.
1 · Reply
TwongStocks
TwongStocks Sep. 25 at 9:40 AM
$KALV Note terms: • Notes mature Oct 1, 2031 • $16.81 Conversion Price of the Notes. • Notes not redeemable before Oct 5 2028 • Between Oct 5 2028 and July 1, 2031 KALV has the option to redeem all or part of the Notes if the stock is trading above $21.853 (130% of the conversion price) for 20 trading days during the 30 day period prior to redemption.
1 · Reply
PokerMunkee
PokerMunkee Sep. 25 at 4:02 AM
$KALV KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 https://ir.kalvista.com/news-releases/news-release-details/kalvista-prices-upsized-offering-1250-million-3250-convertible/
0 · Reply
BioCapitalist99
BioCapitalist99 Sep. 25 at 1:06 AM
$KALV not worried about dilution as this is already a commercial staged pharma company. It provides the fuel for growth. If tomorrow opens very negative (I doubt it though), I'll increase my position by 20/30%
1 · Reply
ALOSETE
ALOSETE Sep. 24 at 10:00 PM
$KALV Fantastics news. Holding for 20$ this year.
1 · Reply
edelhead
edelhead Sep. 24 at 9:30 PM
$KALV This announcement is a very bullish move by the company. This is all in connection with the company's growth spurt that is quickly coming around the globe!
1 · Reply
DonCorleone77
DonCorleone77 Sep. 24 at 9:20 PM
$KALV KalVista announces $110M convertible senior notes offering
1 · Reply
Stocker1988
Stocker1988 Sep. 24 at 8:21 PM
$KALV this offering must be to raise capital for the EU and EC recent approval.
2 · Reply
ucantcatchmegaythots
ucantcatchmegaythots Sep. 24 at 8:12 PM
$KALV damn... well this is dead money for a while
0 · Reply
Goatcheese
Goatcheese Sep. 24 at 8:05 PM
$KALV cash til 2027 and now offering up 110 million in convertible notes, ouch - not holding
0 · Reply